Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

Bruno Bockorny; Teresa Macarulla; Valerya Semenisty; Erkut Borazanci; Jaime Feliú; Mariano Ponz‐Sarvisé; David Gutiérrez Abad; Paul E. Oberstein; Angela Alistar; Andrés Muñoz; Ravit Geva; Carmen Guillén‐Ponce; Mercedes Salgado Fernández; Amnon Peled; Marya Chaney; Irit Gliko-Kabir; Liron Shemesh-Darvish; Debby Ickowicz; Ella Sorani; Shaul Kadosh; Abi Vainstein‐Haras; Manuel Hidalgo

doi:10.1158/1078-0432.ccr-21-0929

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Triple combination of motixafortide, pembrolizumab, and chemotherapy was safe and well tolerated, and showed signs of efficacy in a population with poor prognosis and aggressive disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bockorny et al. (2021) studied this question.

synapsesocial.com/papers/69da44b1387cf706986867d0 https://doi.org/10.1158/1078-0432.ccr-21-0929

View Full Paper

Ask AI

Bookmark

Share

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading